Related Experiment Video
Updated: Sep 11, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Evolving strategies for early diagnosis, proactive prevention and treatment of CKD
Alberto Ortiz1,2,3, Motoko Yanagita4,5, Hideki Yokoi6
1Department of Nephrology and Hypertension, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Insights
Chronic kidney disease (CKD) is a growing cause of death, but new drugs and the ABCDE screening approach can prevent kidney failure. Early detection and treatment of CKD and cardiovascular-kidney-metabolic syndrome are crucial.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Metabolic Syndrome
Background:
- Chronic kidney disease (CKD) is a rapidly growing cause of mortality globally, projected to become the third leading cause of death in Western Europe and Japan by 2050.
- Current kidney replacement therapies (KRT) offer suboptimal outcomes, with significantly reduced life expectancy compared to the general population.
- Cardiovascular medicine has advanced in risk identification and prevention, a model kidney medicine is now adopting for the cardiovascular-kidney-metabolic (CKM) syndrome.
Purpose of the Study:
- To highlight the limitations of 20th-century CKD screening focused solely on diabetes and albuminuria.
- To advocate for the adoption of 21st-century kidney protective drugs and strategies for early CKD detection and CKM syndrome management.
- To propose the concept of 'pre-CKD' to guide preventative pharmacological interventions.
Main Methods:
- Review of current trends in CKD mortality and cardiovascular disease mortality.
- Analysis of the impact of kidney replacement therapy (KRT) on life expectancy.
- Examination of clinical trial data on kidney protective therapies and early CKD diagnosis based on albuminuria and glomerular filtration rate.
Main Results:
- New kidney protective drugs can prevent and slow CKD progression, addressing the CKM syndrome.
- Current CKD screening misses up to 80% of individuals who develop kidney failure due to outdated focus on diabetes.
- Early treatment initiated based on albuminuria, even with normal GFR, can delay KRT by up to 30 years.
Conclusions:
- Widespread adoption of the ABCDE (Albuminuria, Blood pressure, Cholesterol, Diabetes, Estimated GFR) approach is essential for early CKD and CKM risk detection and treatment.
- Developing the concept of 'pre-CKD' will enable targeted pharmacological interventions to prevent CKD.
- Integrating these strategies with healthy lifestyle measures is key to improving outcomes for all individuals, not just those at high risk.
Abstract:
Chronic kidney disease (CKD) is among the fastest growing global causes of death, forecasted to become the third leading cause of death in Western Europe and Japan by 2050. In contrast, mortality from cardiovascular disease is decreasing. Cardiovascular medicine is focused on identifying people at high risk and intervening to prevent cardiovascular events. The focus of kidney medicine has evolved over time. Last century the focus was on treating kidney failure by kidney replacement therapy (KRT). However, KRT outcomes are suboptimal. Life expectancy is up to 44 (women on dialysis) to 22 years (women with functioning kidney grafts) shorter on KRT than in the general population. The 21st century has witnessed an explosion of highly effective kidney-protective drugs that may both prevent and slow the progression of CKD while addressing the full cardiovascular-kidney-metabolic (CKM) syndrome spectrum, i.e. also improving cardiovascular and metabolic outcomes. However, these advances have met a barrier: 20th century concepts on whom to test for CKD, which focus on assessing albuminuria just in people with diabetes mellitus. This outdated concept limits early diagnosis and treatment in up to 80% of people who eventually develop kidney failure. Clinical trials suggest that starting kidney protective therapy because CKD was diagnosed based on albuminuria, when glomerular filtration rate is normal, may delay the need for KRT for up to nearly 3 decades, meaning that many older subjects would not require KRT. To improve outcomes, the next two steps in kidney medicine should involve the widespread adoption of the ABCDE (albuminuria, blood pressure, cholesterol, diabetes and estimated glomerular filtration rate) approach for early detection and treatment of CKM risk, followed by developing the concept of pre-CKD that may guide pharmacologic interventions targeted to prevent CKD, on top of healthy lifestyle measures for the entire population, not just for those at risk.
More Related Videos
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations

